Related Experiment Videos
Clinical toxicities encountered with paclitaxel (Taxol)
E K Rowinsky1, E A Eisenhauer, V Chaudhry
1Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, Baltimore, MD 21287-8934.
Seminars in Oncology
|August 1, 1993
Summary
Paclitaxel (TAXOL) is a promising cancer drug, but neutropenia is its main toxicity. Cardiac and neurotoxic effects are generally manageable, especially with proper patient selection and monitoring.
Area of Science:
- Oncology
- Pharmacology
Background:
- Paclitaxel (TAXOL) shows promise in treating various cancers.
- Limited early supply and hypersensitivity reactions initially hindered its development.
- Effective premedication and administration schemes have mitigated hypersensitivity issues.
Purpose of the Study:
- To review the clinical profile of paclitaxel, focusing on its toxicities.
- To inform oncologists about managing paclitaxel's side effects.
Main Methods:
- Review of clinical trial data and observed patient outcomes.
- Analysis of toxicity profiles, including hypersensitivity, neutropenia, cardiac events, and neurotoxicity.
Main Results:
- Neutropenia is the primary dose-limiting toxicity, typically transient and non-cumulative.
- Cardiac events like bradycardia are observed but often not clinically significant; monitoring is not routinely recommended for low-risk patients.
- Neurotoxicity, primarily peripheral neuropathy, is usually mild to moderate but can be severe in susceptible patients.
Conclusions:
- Paclitaxel is a valuable antineoplastic agent with manageable toxicities.
- Careful patient selection is crucial, particularly for those with pre-existing cardiac or neurological conditions.
- Ongoing monitoring and understanding of toxicity profiles are essential for optimal patient care.